Already have an account? Get multiple benefits of using own account!
Login in your account..!
Don't have an account? Create your account in less than a minutes,
Forgot password? how can I recover my password now!
Enter right registered email to receive password!
Please paraphrase this whole paragraph
In 2011, AstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business. In February 2012, AstraZeneca and Amgen announced a collaboration on treatments for inflammatory diseases. Then in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion. In June 2012, AstraZeneca and Bristol-Myers Squibb announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals. It was agreed that Bristol-Myers Squibb would acquire Amylin for $5.3 billion in cash and the assumption of $1.7 billion in debt, with AstraZeneca then paying $3.4 billion in cash to Bristol-Myers Squibb, and Amylin being folded into an existing diabetes joint-venture between AstraZeneca and Bristol-Myers Squibb. In March 2013 AstraZeneca announced plans for a major corporate restructuring, including the closure of its research and development activities at Adderley Park, investment of $500 million in the construction of a new research and development facility in Cambridge and the concentration of R&D in three locations: Cambridge, Gaithersburg, Maryland and Mondale (near Gothenburg) in Sweden, for research on traditional chemical drugs. AstraZeneca also announced that it would move its corporate headquarters from London to Cambridge in 2016. That announcement included the announcement that it would cut 1,600 jobs; three days later it announced it would cut an additional 2,300 jobs. It also announced that it would focus on three therapeutic areas: Respiratory, Inflammation & Autoimmunity; Cardiovascular & Metabolic Disease; and Oncology. In October 2013, AstraZeneca announced it would acquire biotech oncology company Spirogen for around $440 million. In April 2015 AstraZeneca's drug tremelimumab was approved as an orphan drug for the treatment of mesothelioma in the United States. In February 2016, AstraZeneca announced that a clinical trial of tremelimumab as a treatment for mesothelioma failed to meet its primary endpoint.
Rady Computer Copr produces a 4 week supply of its PC model when stock on hand drops to 500 units. It takes 1 week to produce a batch of this PC model. Fatort order average 40
Name some recent educational innovations and evaluate their effectiveness. Do you think that schools would be more effective if they did not have comply with bureaucratic re
Illustrate what are the problems in scheduling work in a assembly line production covering automatic batch manufacturing. Compare with flexible manufacturing system.
“We feel lucky to be this popular. I think customers feel we have so many options to offer that they ought to rent an auto from us,” says Ricardo Limon, who manages several ou
The company manufactures two types of product A and B made of plastic. The company received 3,000 lbs recycled plastic of product A and 10,800 lbs recycled plastic of product
What remedies are available to a seller or lessor when the buyer or lessee breaches the contract? What remedies are available to a buyer or lessee if the seller or lessor brea
A sporting goods manufacturer is developing a production schedule for two types of racquetball racquets. An order has been received for 180 of the standard model and 90 of the
Describes why you believe that these customer requirements are related to the capabilities of the manufacturing department and how they fit into the business strategy of des
Get guaranteed satisfaction & time on delivery in every assignment order you paid with us! We ensure premium quality solution document along with free turntin report!
All rights reserved! Copyrights ©2019-2020 ExpertsMind IT Educational Pvt Ltd